The estimated Net Worth of David L Barker is at least $1.7 millió dollars as of 7 July 2022. David Barker owns over 44,470 units of Bionano Genomics Inc stock worth over $28,015 and over the last 21 years he sold BNGO stock worth over $1,573,150. In addition, he makes $102,500 as Independent Chairman of the Board at Bionano Genomics Inc.
David has made over 8 trades of the Bionano Genomics Inc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 44,470 units of BNGO stock worth $22,680 on 7 July 2022.
The largest trade he's ever made was selling 50,000 units of Bionano Genomics Inc stock on 28 November 2005 worth over $748,000. On average, David trades about 10,284 units every 364 days since 2004. As of 7 July 2022 he still owns at least 58,364 units of Bionano Genomics Inc stock.
You can see the complete history of David Barker stock trades at the bottom of the page.
Dr. David L. Barker Ph.D. serves as Independent Chairman of the Board of the Company. Dr. Barker has served on our board of directors since May 2010, and as Chairman of our board of directors since August 2016. Dr. Barker also serves as a member of the board of directors of AmideBio, Singular Genomics Systems, Symbiotic Systems, and Aspen Neuroscience. He is also a scientific advisor to MiNDERA Corp. and Luna DNA. He served as Vice President and Chief Scientific Officer at Illumina, Inc., from 2000 to 2007, and on the Illumina scientific advisory board until May 2016. He was previously on the Boards of NextBio, which was acquired by Illumina in 2013, ProteinSimple, which was acquired by Bio-Techne in 2014, Zephyrus Biosciences, Inc., acquired by Bio-Techne in 2016, IntegenX, acquired by Thermo Fisher Scientific in 2018, and Integrated Diagnostics, acquired by Biodesix in 2018. Dr. Barker served from 1998 to 2000 as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University. Our board of directors believes Dr. Barker’s extensive experience in managing and leading early stage and established companies within the clinical diagnostic and biotechnology industries qualifies him to serve on our board of directors.
As the Independent Chairman of the Board of Bionano Genomics Inc, the total compensation of David Barker at Bionano Genomics Inc is $102,500. There are 3 executives at Bionano Genomics Inc getting paid more, with R. Erik Holmlin having the highest compensation of $898,590.
David Barker is 78, he's been the Independent Chairman of the Board of Bionano Genomics Inc since 2016. There are no older and 8 younger executives at Bionano Genomics Inc.
David's mailing address filed with the SEC is C/O BIONANO GENOMICS, INC., 9540 TOWNE CENTRE DRIVE, SUITE 100, SAN DIEGO, CA, 92121.
Over the last 6 years, insiders at Bionano Genomics Inc have traded over $0 worth of Bionano Genomics Inc stock and bought 145,814 units worth $129,149 . The most active insiders traders include David L Barker, Christopher P. Stewart és Christopher J Twomey. On average, Bionano Genomics Inc executives and independent directors trade stock every 75 days with the average trade being worth of $15,253. The most recent stock trade was executed by Hannah Mamuszka on 13 June 2023, trading 65,789 units of BNGO stock currently worth $50,000.
at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o
Bionano Genomics Inc executives and other stock owners filed with the SEC include: